Aethlon Medical - 9 Year Stock Price History | AEMD
Historical daily share price chart and data for Aethlon Medical since 2015 adjusted for splits and dividends. The latest closing stock price for Aethlon Medical as of April 23, 2024 is 1.51.
- The all-time high Aethlon Medical stock closing price was 1707.00 on July 24, 2015.
- The Aethlon Medical 52-week high stock price is 5.00, which is 231.1% above the current share price.
- The Aethlon Medical 52-week low stock price is 1.35, which is 10.6% below the current share price.
- The average Aethlon Medical stock price for the last 52 weeks is 2.43.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Aethlon Medical Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2024 |
1.7507 |
2.1650 |
2.1800 |
1.4150 |
1.5119 |
-30.96% |
| 2023 |
3.3312 |
2.8590 |
6.9990 |
1.4200 |
2.1900 |
-20.48% |
| 2022 |
10.4600 |
19.6000 |
19.9000 |
2.4800 |
2.7540 |
-85.19% |
| 2021 |
30.9155 |
25.2000 |
107.9000 |
15.4000 |
18.6000 |
-24.70% |
| 2020 |
17.6388 |
12.5000 |
43.4000 |
11.2000 |
24.7000 |
156.49% |
| 2019 |
82.3809 |
237.0000 |
237.0000 |
8.3580 |
9.6300 |
-96.13% |
| 2018 |
193.0364 |
174.0000 |
285.0000 |
140.0250 |
249.0000 |
46.90% |
| 2017 |
329.9178 |
602.7000 |
712.5000 |
120.1500 |
169.5000 |
-73.10% |
| 2016 |
806.6219 |
945.0000 |
1154.9999 |
616.5000 |
630.0000 |
-38.14% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Health Maintenance Organizations |
$0.004B |
$0.001B |
|
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
|
